The takeaway is not that GLP-1s failed, but that Alzheimers disease is harder than metabolic disease, and likely requires earlier, smarter, and multi-modal strategies
Keep a close eye on GLP-1 market dynamics , especially Lilly's ability to maintain market share against competitors like Novo Nordisk (NYSE: NVO), and anticipate clinical trial readouts for pipeline candidates like the oral GLP-1, orforglipron, and retatrutide
The retatrutide buyers I interviewed said they welcome the legitimate stuffthough they expect it to be incredibly expensive
Factors that affect your timeline: - Severity and age of the injury - If you're doing physical therapy alongside the stack - Nutrition quality (adequate protein, vitamin C, zinc) - Sleep quality - Compliance with the full protocol Track your healing progress in the with pain scores, range of motion, and function notes
Key Takeaway: The synergy between L-carnitine and vitamin C focuses on energy efficiency